Related Experiment Video
Updated: Jun 28, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.4K
A Glucose-Responsive Cannula for Automated and Electronics-Free Insulin Delivery
Stephanie Fuchs1, Julia S Caserto2, Qingsheng Liu1
1Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA.
Advanced Materials (Deerfield Beach, Fla.)
|April 19, 2024
Summary
Researchers developed an innovative, electronics-free glucose-responsive cannula for automated insulin delivery. This smart cannula simplifies diabetes management by releasing insulin based on glucose levels, reducing the burden of care.
Area of Science:
- Biomaterials Science
- Medical Devices
- Endocrinology
Background:
- Automated insulin delivery systems revolutionize diabetes treatment but face challenges like cost and complexity.
- Current systems often require separate sensors, electronics, and significant user interaction.
Purpose of the Study:
- To develop and evaluate a user-centric, electronics-free glucose-responsive cannula for automated insulin delivery.
- To create a simpler, more accessible alternative to existing insulin delivery technologies.
Main Methods:
- Fabrication of a glucose-responsive cannula using a hybrid elastomer-hydrogel membrane via a one-pot solvent exchange method.
- Evaluation of two cannula prototypes in insulin-deficient diabetic mouse models.
- Assessment of blood glucose normalization and postprandial glucose control.
Main Results:
- The developed cannula demonstrated permeability changes in response to physiological glucose variations, enabling insulin release.
- The first prototype normalized blood glucose levels for 3 days in diabetic mice.
- The second, more translatable prototype also showed effective 3-day glucose regulation with twice-daily refilling.
Conclusions:
- The glucose-responsive cannula offers a promising approach for electronics-free, automated insulin delivery.
- This technology has the potential to reduce the burden of care and cost associated with insulin-dependent diabetes management.
- This proof-of-concept study paves the way for next-generation "smart" cannulas and insulin therapies.
Related Concept Videos
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Insulin Formulations: Types and Delivery
192
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
192
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154

